Please login to the form below
BioMarin
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
A new era in haemophilia approaches. Yesterday’s big news came from two rival developing gene therapies which could represent a cure for haemophilia – Spark Therapeutics and BioMarin. ... BioMarin meanwhile also provided long-term data on its
Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more
Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more. ... records. NEW RARE DISEASE APPROVAL. BioMarin sees blockbuster potential for newly-approved Palynziq.
More encouraging data for Spark and Pfizer’s potential haemophilia B cure
Here BioMarin looks to have the edge, with its valoctocogene roxaparvovec or ‘valrox’, formerly BMN 270 producing superior results to Spark’s own SPK-8011.
BioMarin ups the ante for pivotal haemophilia gene therapy trial
BioMarin ups the ante for pivotal haemophilia gene therapy trial. Adds another 90 patients to the GENEr8-1 registration study. ... There were also dramatic improvements in quality of life which BioMarin said stemmed from “cessation of bleeding, freedom
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
-
Scientific Engagement Director
-
Salary will be dependant on experience
- Account Director, Training & Medical Communications, London
-
Competitive Salary
- Science Writer – Healthcare Advertising
-
Salary TBC
- Senior Strategic Planner, Healthcare Brand Communications, Londo...
-
Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Multi-Channel Account Managers - Road / Home-office based – Full...
-
Competitive salary
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Medical Writer, Healthcare Advertising
-
£35 - £45, 000 benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
Subscribe to our email news alerts
- Roche starts new late-stage trials of Alzheimer’s candidate
- AbbVie, Roche get FDA OK for broader use of Venclexta
- Moving annual total (MAT)
- UK pharma cheers EU science announcement
- AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
- Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS
- NICE set to reject Kyowa Kirin’s Crysvita for XLH
- More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
- UK firm Nightstar bags FDA fast-track status for gene therapy
- British Business Bank sets up £2.5bn fund for ‘unicorn’ firms
- Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte
- Anthill Agency launch digital-focused academy
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Australian Flu and the dilemma of naming diseases
- ...
- Wearables and Healthcare
- What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
- What does a future-proof rep look like?
- Businesses can no longer afford to push ahead with the traditional Key Account Management model....
Quick links
Infographics
